Statement of Changes in Stockholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Jun. 30, 2019	$ 256	$ 3,845	$ 102,712,845	$ (92,116,586)	$ 10,600,360
Balance (in shares) at Jun. 30, 2019	255,714	3,844,921
Series A Preferred Stock issued for employee stock compensation			51,398		51,398
Series A Preferred Stock issued for employee stock compensation (in shares)	387
Common stock issued for consulting and legal services rendered		$ 6	26,994		27,000
Common stock issued for consulting and legal services rendered (in shares)		6,201
Warrants issued to Scientific Advisory Board			908		908
Common shares issued for Directors fees		$ 3	11,247		11,250
Common shares issued for Directors fees (in shares)		2,553
Net loss				(1,561,133)	(1,561,133)
Balance at Sep. 30, 2019	$ 256	$ 3,854	102,803,392	(93,677,719)	9,129,783
Balance (in shares) at Sep. 30, 2019	256,101	3,853,675
Balance at Jun. 30, 2019	$ 256	$ 3,845	102,712,845	(92,116,586)	10,600,360
Balance (in shares) at Jun. 30, 2019	255,714	3,844,921
Net loss					(3,488,659)
Balance at Dec. 31, 2019	$ 366	$ 3,871	103,323,412	(95,605,245)	7,722,404
Balance (in shares) at Dec. 31, 2019	366,488	3,870,572
Balance at Sep. 30, 2019	$ 256	$ 3,854	102,803,392	(93,677,719)	9,129,783
Balance (in shares) at Sep. 30, 2019	256,101	3,853,675
Series A Preferred Stock issued for employee stock compensation			49,394		49,394
Series A Preferred Stock issued for employee stock compensation (in shares)	387
Series A Preferred Stock issued for accounts payable-related party	$ 100		392,569		392,669
Series A Preferred Stock issued for accounts payable-related party (in Shares	100,000
Series A Preferred Stock issued for loan origination fee	$ 10		39,291		39,301
Series A Preferred Stock issued for loan origination fee (in shares)	10,000
Common stock issued for consulting and legal services rendered		$ 12	26,988		27,000
Common stock issued for consulting and legal services rendered (in shares)		11,932
Warrants issued to Scientific Advisory Board			533		533
Common shares issued for Directors fees		$ 5	11,245		11,250
Common shares issued for Directors fees (in shares)		4,965
Net loss				(1,927,526)	(1,927,526)
Balance at Dec. 31, 2019	$ 366	$ 3,871	103,323,412	(95,605,245)	7,722,404
Balance (in shares) at Dec. 31, 2019	366,488	3,870,572
Balance at Jun. 30, 2020	$ 369	$ 9,083	127,311,634	(105,563,124)	21,757,962
Balance (in shares) at Jun. 30, 2020	368,602	9,083,414
Series A Preferred Stock issued for employee stock compensation	$ 0	$ 0	53,098	0	53,098
Series A Preferred Stock issued for employee stock compensation (in shares)	387	0
Net proceeds from issuance of common stock in connection with equity financings		$ 1,576	10,440,640		10,442,216
Net proceeds from issuance of common stock in connection with equity financings (in shares)		1,575,342
Common stock issued for consulting and legal services rendered		$ 5	26,995		27,000
Common stock issued for consulting and legal services rendered (in shares)		5,135
Warrants issued to Scientific Advisory Board			1,986		1,986
Common shares issued for Directors fees		$ 2	11,248		11,250
Common shares issued for Directors fees (in shares)		2,040
Net loss				(2,311,233)	(2,311,233)
Balance at Sep. 30, 2020	$ 369	$ 10,666	137,845,601	(107,874,357)	29,982,279
Balance (in shares) at Sep. 30, 2020	368,989	10,665,931
Balance at Jun. 30, 2020	$ 369	$ 9,083	127,311,634	(105,563,124)	21,757,962
Balance (in shares) at Jun. 30, 2020	368,602	9,083,414
Net loss					(4,641,287)
Balance at Dec. 31, 2020	$ 369	$ 10,677	137,939,407	(110,204,411)	27,746,042
Balance (in shares) at Dec. 31, 2020	369,376	10,677,448
Balance at Sep. 30, 2020	$ 369	$ 10,666	137,845,601	(107,874,357)	29,982,279
Balance (in shares) at Sep. 30, 2020	368,989	10,665,931
Series A Preferred Stock issued for employee stock compensation			50,602		50,602
Series A Preferred Stock issued for employee stock compensation (in shares)	387
Common stock issued for consulting and legal services rendered		$ 7	26,993		27,000
Common stock issued for consulting and legal services rendered (in shares)		7,411
Warrants issued to Scientific Advisory Board			1,215		1,215
Common shares issued for Directors fees		$ 4	14,996		15,000
Common shares issued for Directors fees (in shares)		4,106
Net loss				(2,330,054)	(2,330,054)
Balance at Dec. 31, 2020	$ 369	$ 10,677	$ 137,939,407	$ (110,204,411)	$ 27,746,042
Balance (in shares) at Dec. 31, 2020	369,376	10,677,448